1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
| Autor: | Saad, F., Armstrong, A.J., Thiery-Vuillemin, A., Oya, M., Shore, N.D., Procopio, G., Arslan, C., Mehra, N., Parnis, F., Brown, E., Constans Schlurmann, F., Joung, J.Y., Sugimoto, M., Sartor, O., Liu, Y-Z., Poehlein, C.H., Desai, C., Del Rosario, P.M.D., Clarke, N. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1160-S1160 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|